Celemics, Inc (331920) Fair Value & Analysis
Healthcare · KR · Market cap 170B KRW
Fair value as of: Jun 24, 2026
Analysis
Celemics, Inc (331920) currently trades at 12,130 KRW, while our model-based Fair Value estimate is 3,705 KRW — implying the stock looks roughly 69.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea. The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase. It also provides celemics analysis, whole exome sequencing, customized NGS panels, sequencing, bioinformatics, biopharma, and custom NGS assay development services. Its products are used in oncology, liquid biopsy, biopharma solutions, inherited diseases, pharmacogenomics, virus research, agrigenomics, RNA sequencing, epigenetics, metagenomic sequencing, antibody discovery, and bioinformatics applications. The company was founded in 2010 and is headquartered in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Celemics, Inc (331920) undervalued?
What is the fair value of 331920?
What is the quality score of 331920?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.